Pharmaceutical compositions comprising WRN helicase inhibitors

Inventors

Kikuchi, Shota • Lam, Betty • Green, Jason • Rogness, Don • Weinstein, David • Burgess, Larry • HORNING, Benjamin • Lamb, Kelsey • Owyang, Zachary • Malmstrom, Robert

Assignees

Vividion Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12187685-B2

Patent

Publication Date

2025-01-07

Expiration Date


Abstract

Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

Core Innovation

The invention relates to Formula (I) compounds, or pharmaceutically acceptable salts thereof, with a pyrimidine-5-carboxamide scaffold and extensive structural variability. X is N and Y is N, while Z is CR5, or Y and Z taken together form an optionally substituted five- to six-membered heteroaryl or heterocyclyl. The compounds further vary at R1, R3, R5, and W/W1-W5, including optional ring-forming constraints and defined (Z)- or (E)-geometric isomerism.

The disclosure includes phenoxypyrimidine-5-carboxamide derivatives and related substituted pyrimidine carboxamides with named stereochemical embodiments such as (S,E), (E), and (Z) forms. The examples describe cycloalkyl, heterocyclyl, heteroaryl, phenoxy, and methylsulfonyl allyl substituent patterns, together with stereoisomeric and peak-separated products. Reported compounds include cyclobutyl, cyclopentylmethyl, spiro, tetrahydropyran, bicyclo[4.2.0]octa-1,3,5-trienyl, azetidinyl, and difluoro-substituted variants.

The examples provide specific compound embodiments, synthetic intermediates, and analytical verification such as LC-MS [M+1] m/z values, chiral HPLC, chiral SFC, and Prep-HPLC separation. The disclosure also includes substituted pyrimidine/imidazo-/pyrazolo-/nicotinamide carboxamides, a spiro-fused system, and compounds bearing a phenoxy group and an (E)-1-methyl-3-methylsulfonyl-allyl side chain.

Claims Coverage

The provided material centers on a Formula (I) compound scaffold with multiple structural variables and ring-forming options, and includes additional independent compound claims stated only as compounds of formula without the full formula text. The independent coverage uses X, Y, Z, R1, R3, R5, and W/W1-W5, with explicit (Z)/(E) geometric-isomer allowances and optional pharmaceutically acceptable salt coverage.

Formula (I) compound scaffold with heteroatom and ring constraints

A compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is N, Y is N, and Z is CR5, or Y and Z taken together form an optionally substituted five- to six-membered heteroaryl or heterocyclyl.

Variable R1 with optional ring formation

R1 is H, or an O-linked optionally substituted C3-C8 cycloalkyl, C1-C6 alkyl, C6-C10 aryl, five- to six-membered heteroaryl, or five- to six-membered heterocyclyl, or optionally substituted C3-C8 cycloalkyl; or R1 together with the carbon atoms to which it is shown attached and X form an optionally substituted five- to six-membered heterocyclyl.

Variable R3 with optional ring formation

R3 is selected from optionally substituted C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C10 aryl, C1-C6 alkyl, C1-C6 alkenyl, —NR2, —N(R)(optionally substituted C3-C8 cycloalkyl), —S-(optionally substituted C1-C6 alkyl), —O-(optionally substituted C1-C6 alkyl), —O-(optionally substituted C3-C8 cycloalkyl), optionally substituted four- to six-membered heterocyclyl or heterocyclenyl, or optionally substituted five- to six-membered heteroaryl; or R3 together with the carbon atom to which it is shown attached and Y form an optionally substituted five- to six-membered heterocyclyl or heterocyclenyl.

Variable R5 selection

R5 is H, C1-C6 alkyl, —NR2, or —N(R)C(=O)(C1-C6 alkyl).

W substructure selection with E/Z isomerism

W is W1, W2, W3, W4, or W5, where W1, W2, and W5 include bonds that can exist as either a (Z)- or (E)-geometric isomer.

Ring-forming W definitions

W1, W2, W3, W4, and W5 define substituent variables and ring-forming outcomes, including azetidinyl, azetidinyl or pyrrolidinyl, dihydropyrrolyl, and 1,1-dioxido-2H-thietyl ring systems.

Additional W5 constraints

In W5, the bond can exist as either a (Z)- or (E)-geometric isomer, m is 1, 2, or 3, and R19 is selected from C1-C6 alkyl and —O—(C1-C6 alkyl).

Independent compound claims of formula

Additional independent claims are directed to a compound of formula, or a pharmaceutically acceptable salt thereof, with the exact formula not provided in the input text.

The claim coverage is anchored in a broad Formula (I) small-molecule scaffold defined by X/Y/Z heteroatom placement, R1/R3/R5 substituent classes with optional ring formation, and W1-W5 substructures with explicit (Z)/(E) geometric-isomer allowances. The input also includes additional independent compound-of-formula claims and dependent pharmaceutical composition coverage with pharmaceutically acceptable carriers or excipients.

Stated Advantages

Pharmaceutical composition use with a pharmaceutically acceptable carrier or excipient.

Cancer treatment and proliferative disease context associated with WRN helicase inhibition.

WRN helicase activity assay and ATP-related context.

Covalent inhibition of WRN helicase through engagement of Cys727 in SEQ ID NO:1.

Documented Applications

Pharmaceutical composition use with a pharmaceutically acceptable carrier or excipient.

Cancer treatment and proliferative disease context associated with WRN helicase inhibition.

WRN helicase activity assay and ATP-related context.

Covalent inhibition of WRN helicase through engagement of Cys727 in SEQ ID NO:1.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.